InvestWiser

Nykode Therapeutics ASA

NYKDOslo BørsHealthcareMarket value 1.1 bn NOK
2.74NOK 0.0%
last day · Price as of 18 November 2026

The answer first

Does Nykode Therapeutics beat the market?

No, Nykode Therapeutics has not beaten the market over the last year.

Nykode Therapeutics+25.0%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 10% of Nordic stocks

    • Quality34
    • Value13
    • Trend37

    No. 163 of 195 in healthcare

Max for seven days

Follow Nykode Therapeutics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Nykode Therapeutics

From today, at a price of 2.74 NOK. Write why you follow Nykode Therapeutics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Nykode Therapeutics

Your first answer is free, no account needed.

Do you own Nykode Therapeutics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Nykode Therapeutics and a few more. Free, no card.

Past year against the exchange and Super Stock
Nykode Therapeutics+25.0%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Nykode Therapeutics has risen 25.0% over the past year, including dividends.
  • Overall, Nykode Therapeutics ranks better than 10% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 97.4%. The price is 95.4% below its peak now.

Who owns Nykode Therapeutics? See the major shareholders and their stakes

What do analysts think of Nykode Therapeutics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

10

Quality, value and trend together. Better than 10% of Nordic stocks.

No. 163 of 195 in healthcare

Quality34
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 154 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.21
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−28.6%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value13
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 126 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.1
  • P/SPrice divided by sales552.6
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend37
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 91 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−39.2%
  • 6 months−18.5%
  • 9 months−26.4%
  • 12 months+25.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−13.8%
3 years, per year
−38.0%
5 years, per year
−42.9%
Year to date
+13.6%
Largest fall, 3 years
−97.4%
From a peak to the bottom
From the peak now
−95.4%
How far the price is from the peak
Volatility, 1 year
83.7%
How much the price swings over a year
Beta, 1 year
0.89
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Nykode Therapeutics

6 funds we follow own Nykode Therapeutics. The share is how much of the fund the stock makes up.

  • Norway5
  • Sweden1

From the funds' latest known holdings.

About Nykode Therapeutics

Nykode Therapeutics ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 59 employees.

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

See the full analysis of Nykode Therapeutics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market